Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Abeona Therapeutics Inc (ABEO) vs Ryanair Holdings plc (RYAAY) Price & Performance

Abeona Therapeutics IncTrade
Ryanair Holdings plcTrade

Price performance (Past 24H)

Key statistics

Abeona Therapeutics Inc vs Ryanair Holdings plc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $424.33M), while Ryanair Holdings plc trades at $60.24 (market cap $29.86B). The key difference: Ryanair Holdings plc is far larger — about 70.4× Abeona Therapeutics Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.

ABEORYAAY
Market Cap
$424.33M$29.86B
Sector
HealthIndustrials
52-Week High
$7.45$73.82
52-Week Low
$4.17$53.24
Enterprise Value
$279.23M$26.83B
Dividend Yield
1.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Abeona Therapeutics Inc

ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.

Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.

Ryanair Holdings plc

RYAAY trades at $60.19, down 0.59% on the day, with a neutral technical signal and bearish moving averages. The company reported mixed quarterly earnings, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Fundamentals show strong profitability with a 12.13% net margin and 22.41% ROE, supported by $13.95B revenue in 2025. Analyst sentiment is positive with a 62.5% buy rating, though recent news highlights pressure from lower fares and higher fuel costs.

The outlook for RYAAY is cautiously optimistic, with potential upside from industry consolidation and a strong balance sheet, but near-term risks include volatile fuel prices, competitive pricing pressure, and geopolitical tensions affecting travel demand. The stock's valuation at a P/E of 14.56 appears reasonable if earnings stabilize.

Returns comparison

Trailing returns across standard periods

About Abeona Therapeutics Inc

Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.

Read more on ABEO

About Ryanair Holdings plc

Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.

Read more on RYAAY